Board's Extensive Governance & Leadership Experience to Help Propel NAYA Towards Transformative Near-Term Milestones

MIAMI, FL / ACCESS Newswire / March 17, 2026 / NAYA Therapeutics, a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer therapies through the development of astatine-211 (²¹¹At) targeted alpha therapies and natural killer (NK) cell engaging bifunctional antibodies, today announced that it has elected a new board of directors to support its management team as it accelerates company growth towards transformative clinical milestones.

"We are thrilled to have attracted such a world-class board of directors committed to NAYA's development as a leading oncology company" commented NAYA Chairman of the Board & Chief Executive Officer Dr. Daniel Teper. "This team brings a combination of clinical development, supply chain, venture investment, and corporate governance experience poised to help translate NAYA's scientific excellence into near-term clinical and commercial success."

The newly elected members of the board joining Chairman Dr. Daniel Teper are:

Ely Benaim, MD, an accomplished physician-executive with over 25 years of experience in oncology drug development and clinical leadership. A pediatric hematologist/oncologist, he has held senior roles at leading biotechnology and pharmaceutical companies, including Amgen, Millennium/Takeda, Novocure, and SonALAsense. Dr. Benaim currently serves as Chief Medical Officer of Henlius Fosun USA, where he leads U.S. clinical strategy and development initiatives. His career is distinguished by bringing multiple innovative cancer treatments from early clinical trials to FDA approval, improving outcomes for patients worldwide

Margarita Chavez, JD, a seasoned biopharmaceutical executive with over 25 years of dealmaking experience in the healthcare industry, including in biotech licensing, IPOs, and acquisitions. Margarita currently serves on the boards of Aligos Therapeutics and chairs the Strategy Committee, Newron Pharmaceuticals and chairs the BD Committee, and Xylo Bio as Board Chair. She is also Managing Partner of Ilustrada Group, a biotech advisory. Margarita served as Managing Director at AbbVie Ventures and was responsible for investments in Morphic Therapeutics (acquired by Lilly for $3.2Bn), Alector Therapeutics, Jnana Therapeutics (acquired by Otsuka for $1.1Bn), and Accent Therapeutics, among others. As a Director on the Licensing & Acquisitions team of Abbott/AbbVie, Margarita was involved in the in-licensing of Oralissa, and the acquisitions of Immuven, Solvay, and the Lupron franchise. Early in her career, Margarita practiced as a corporate and securities lawyer, advising clients on mergers, acquisitions, public and private financings at Brobeck, Phleger & Harrison LLP in Silicon Valley.

Anne Lauvergeon, PhD, a leading businesswoman, board member, and political advisor. Anne is the founder and President of ALP (Anne Lauvergeon Partners), an advisory and investment company mostly dedicated to innovation. She has served on over a dozen boards, including American Express, Airbus, Vodafone and TotalEnergies. She was twice named by Time Magazine as one of the 100 most influential people in the world. She previously served as chairman and Chief Executive Officer of global nuclear energy leader AREVA. During her tenure, she initiated the application of nuclear energy to medicine under AREVA Med, which later transformed into radiopharmaceutical leader Orano Med. Some of her previous roles include Partner at Lazard, the world's largest independent investment bank, President of the French Government's 2030 Innovation Commission, which oversees €54 billions of planned investment, and Senior Advisor & Deputy Chief-of-Staff to the French President.

Rahul Singhvi, PhD, MBA, a global leader in the life sciences industry. Rahul was previously cofounder & CEO of biomanufacturing company National Resilience, Inc., where he helped raise over $2 Billion. Prior to co-founding Resilience in 2020, Rahul was an Operating Partner at Flagship Pioneering, where he was responsible for founding and operating companies launched from Flagship Labs. Before joining Flagship, Rahul served as the Chief Operating Officer of the vaccine business unit at Takeda Pharmaceutical Co., where he was responsible for worldwide vaccine CMC and manufacturing operations. Before Takeda, Rahul was President and CEO of Novavax, Inc. and held several positions with Merck & Co in R&D and manufacturing. Rahul graduated as the top ranked chemical engineer from Indian Institute of Technology (IIT), Kanpur and earned both his masters and doctoral degrees in Chemical Engineering from MIT. He earned his MBA from the Wharton School at the University of Pennsylvania where he graduated as a Palmer Scholar. Rahul serves on the Board of Directors for Codexis, and Kairos Pharmaceuticals.

About NAYA

NAYA Therapeutics is a biopharmaceutical company pioneering the next generation of cancer therapies, aiming to unlock deep, durable cures that eradicate residual disease and help patients finish their fight against cancer. NAYA's pipeline harnesses the transformational potential of two synergistic modalities, Astatine-211 (²¹¹At) targeted alpha therapies & NK-cell-engaging bifunctional antibodies, with an initial focus on hepatocellular carcinoma (HCC) & multiple myeloma. Find out more at www.nayatx.com.

NAYA Media & Investor Contact

Lyn Falconio, Chief Communications Officer
917-575-1844
lyn@nayatx.com

SOURCE: NAYA Therapeutics